Ipilimumab for Early-Stage Melanoma?

Despite promising results, experts believe it's too early to use ipilimumab for early-stage melanoma, high toxicity being one of the limiting factors.
Published Online: June 04, 2014

For the first time, ipilimumab (Yervoy, Bristol-Myers Squibb) has been shown to be effective in an adjuvant setting for earlier-stage melanoma. The drug is already approved for use in stage IV disease.

In a new study, known as EORTC 18071, more than 900 patients with stage III disease received ipilimumab (10 mg/kg) at a dose higher than the dose approved (3 mg/kg) for stage IV disease. Results presented here at the 2014 Annual Meeting of the American Society of Clinical Oncology® show that ipilimumab significantly delayed recurrence, compared with placebo, in these stage III patients.

But experts say that these results are not strong enough to catapult the immunotherapy into the role of an important treatment option in this setting. And they cite the drug's toxicity as an ongoing concern, given the marginal benefit shown so far.

Read the original report here: 

Source: Medscape

Recommended Articles
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.
Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.
Fifty years ago today, President Lyndon B. Johnson signed the law that created Medicare and Medicaid, setting in motion not only the greatest change in healthcare in the nation's history at that point, but also a lasting change for society.